Treatment for alcoholic liver disease

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44AA019876-02
Agency Tracking Number: R44AA019876
Amount: $2,052,340.00
Phase: Phase II
Program: SBIR
Awards Year: 2011
Solitcitation Year: 2011
Solitcitation Topic Code: NIAAA
Solitcitation Number: PA10-050
Small Business Information
ANGION BIOMEDICA CORPORATION
51 Charles Lindbergh Blvd, Uniondale, NY, -
Duns: 053129065
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 BERT OEHLEN
 (516) 326-1200
 boehlen@angion.com
Business Contact
 BERT OEHLEN
Phone: (516) 326-1200
Email: boehlen@angion.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver. Over time it frequently progresses to cirrhosis, an end-stage lethal disease which is the seventh leadingcause of death in the United States and afflicts hundreds of millions of people worldwide. Alcohol intake remains the most important cause of liver cirrhosis in Western countries. Alcoholic liver disease can be divided in various stages of development: (1) mild alcoholic liver injury, (2) steatosis, (3) alcoholic hepatitis, (4) alcoholic liver fibrosis and (5) cirrhosis. Although several pharmacological therapies have been tried in patients with alcoholic liver disease, none of the therapeutics so far hasshown consistent improvement in the course of alcoholic liver damage and there remains a major unmet medical need for effective therapies. In our preliminary data, we show that modulators of endogenous ATRA levels have anti-fibrotic activity in mice. We have identified a novel series of ATRA modulators with excellent in vitro and in vivo pharmacological properties and demonstrate its anti-fibrotic activity in vivo. We propose to pursue the lead compound from this series towards an IND nomination as a potential therapeutic for alcoholic liver disease. PUBLIC HEALTH RELEVANCE: Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver caused by sustained immoderate alcohol consumption. Over time it frequently progresses to cirrhosis, an end- stage lethal disease which is the seventh leading cause of death in the United States and afflicts hundreds of millions of people worldwide. There is no therapeutic that shows consistent improvement in the courseof alcoholic liver damage and there remains a major unmet medical need for effective therapies. In our preliminary data, we show that modulators of endogenous ATRA levels have anti-fibrotic activity in mice and that we have identified a novel, in vivo efficacious, series of ATRA modulators. We propose to pursue the lead compound from this series towards an IND nomination as a potential therapeutic for alcoholic liver disease.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government